思派健康2024中期报告

Stock code: 0314(A company incorporated in the Cayman Islands with limited liability) Interim Report Corporate Information22024 First Half Highlights20246Financial Summary7Management Discussion and Analysis9Other Information24Independent Auditor’s Review Report38Interim Condensed Consolidated Statement of Profit orLoss and Other Comprehensive Income40Interim Condensed Consolidated Statement of Financial Position42Interim Condensed Consolidated Statement of Changes in Equity44Interim Condensed Consolidated Statement of Cash Flows46Notes to Interim Condensed Consolidated Financial Information49Definitions75 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors Mr. MA Xuguang(Chairman of the Board)Mr. LI Ji Non-executive Director Mr. YAO Leiwen Independent Non-executive Directors CHANG Stanley Yi2024521 Mr. FAN XinMr. HE HaijianMs. HUANG BeiMr. CHANG Stanley Yi, alias(resigned on May 21, 2024) REMUNERATION AND APPRAISAL COMMITTEE Mr. HE Haijian(Chairman)Ms. HUANG BeiMr. LI Ji NOMINATION COMMITTEE Mr. MA Xuguang(Chairman)Mr. FAN XinMr. HE HaijianMr. CHANG Stanley Yi, alias(resigned on May 21, 2024) CHANG Stanley Yi2024521 AUDIT COMMITTEE Mr. HE Haijian(Chairman)Mr. FAN XinMs. HUANG BeiMr. CHANG Stanley Yi, alias(resigned on May 21, 2024) CHANG Stanley Yi2024521 STRATEGY COMMITTEE Mr. MA Xuguang(Chairman)Mr. LI JiMr. YAO Leiwen JOINT COMPANY SECRETARIES Ms. REN NaMs. LI Ching Yi AUTHORISED REPRESENTATIVES Mr. LI JiMs. LI Ching Yi COMPANY WEBSITEwww.medbankshealthtech.com www.medbankshealthtech.com REGISTERED OFFICE Campbells Corporate Services LimitedFloor 4, Willow House, Cricket SquareGrand Cayman KY1-9010Cayman Islands Campbells Corporate Services LimitedFloor 4, Willow House, Cricket SquareGrand Cayman KY1-9010Cayman Islands C O R P O R A T E I N F O R M A T I O N PRINCIPAL PLACE OF BUSINESS IN THE PRC 7/F, Building 3Xingguangyao PlazaNo. 1888, Caoyang RoadPutuo District, ShanghaiPRC 188837 PRINCIPAL PLACE OF BUSINESS IN HONG KONG 19th Floor, Golden Centre188 Des Voeux Road CentralHong Kong 18819 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Campbells Corporate Services LimitedFloor 4, Willow House, Cricket SquareGrand Cayman, KY1-9010Cayman Islands Campbells Corporate Services LimitedFloor 4, Willow House, Cricket SquareGrand Cayman, KY1-9010Cayman Islands HONG KONG BRANCH SHARE REGISTRAR Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 1617 LEGAL ADVISERS As to Hong Kong and U.S. laws 131 O’Melveny & Myers31/F, AIA Central1 Connaught Road CentralHong Kong As to PRC law Jingtian & Gongcheng34/F, Tower 3, China Central Place77 Jianguo RoadChaoyang District, BeijingPRC 77334 As to Cayman Islands law Campbells1301, 13/FYork House, The Landmark15 Queen’s Road CentralHong Kong Campbells15131301 AUDITOR Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditors27/F One Taikoo Place979 King’s RoadQuarry BayHong Kong 97927 STOCK CODE 03140314 2024 FIRST HALF HIGHLIGHTS2024 During the first half of 2024, the Company continued to focus onachieving organic growth and improving operational efficiency in its corebusinesses, while maintaining ongoing investment in overall digitalizationand synergy development. We successfully achieved sustained growthas we remained steadfast in our development strategy and adapted tothe environment quickly. 2024 Below are the highlights and major achievement we made during theReporting Period: •2023+69.6%83.93.5%2,280.05.5% •Strategic streamlining of medication distribution businessto focus efforts on core business.Starting from the secondhalf of 2023, the management decided to streamline themedication distribution business under the business line ofSpecialty Pharmacy Business. The management no longerconsidered such business to be in line with the Company’s long-term development strategies designed based on the “healthinsurance plus healthcare management” model. Such initiativehas enabled us to focus efforts further on optimizing the corebusiness with enhanced working capital efficiency. As a result,revenue generated from medication distribution business duringthe Reporting Period declined by approximately 69.6% toapproximately RMB83.9 million, accounting for only approximately3.5% of the Group’s consolidated revenue generated during theReporting Period. The core business of the Company, namelySpecialty Pharmacy Business (excluding medication distributionbusiness), Physician Research Assistance Business and HealthInsurance Services Business generated revenue of approximatelyRMB2,280.0 million, representing an increase of approximately5.5%. •20246 30933,000202443.6%2024 •Vigorous growth achieved in Enterprise Health InsuranceBusiness fueled by the synergy developed through the“Dual-Drivers” model.As of June 30, 2024, more than933,000 individual members were insured under EnterpriseHealth Insurance. Revenue generated from Enterprise HealthInsurance increa